Sinovac Presents at Rodman & Renshaw Annual China Investment Conference

  • Date: 2011-03-01
  • Pageview: 9508

BEIJING, March 1, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq:SVA - News), a leading provider of biopharmaceutical products in China, announced today that Mr. Jacob Ho, Acting Chief Financial Officer, Ms. Helen Yang, Investor Relations Manager, and Ms. Chris Lee, Investor Relations, are scheduled to present at the Rodman & Renshaw Annual China Investment Conference.  The conference will be held in Shanghai from March 6th to 8th.  The Sinovac team will present at 11:30 am China Standard Time on March 7th and will participate in one-on-one meetings that day.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received the orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), Japanese Encephalitis, animal and human rabies, HIB and epidemic meningitis, chickenpox, mumps and rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines and has completed the field trials for an independently developed inactivated animal rabies vaccine, which is anticipated to be launched into market in 2011.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

 

Helen Yang / Chris Lee

Sinovac Biotech Ltd.

Tel:  +86-10-8279-9871 / 9659

Fax:  +86-10-6296-6910

Email: ir@sinovac.com

 

Investors:

Stephanie Carrington/Amy Glynn

The Ruth Group

Tel:  +1-646-536-7017/7023

Email: scarrington@theruthgroup.com

aglynn@theruthgroup.com

 

Media

Jason Rando

The Ruth Group

Tel:  +1-646-536-7025

Email:  jrando@theruthgroup.com

Bookmark and Share

Copyright © 2001-2018 Sinovac Biotech Ltd. All Rights Reserved.

Add: No. 39 Shangdi Xi Road, Haidian District, Beijing, P.R.C. 100085